Unknown

Dataset Information

0

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.


ABSTRACT: Preclinical studies of human immunodeficiency virus type 1 (HIV-1) vaccine candidates have typically shown post-infection virological control, but protection against acquisition of infection has previously only been reported against neutralization-sensitive virus challenges. Here we demonstrate vaccine protection against acquisition of fully heterologous, neutralization-resistant simian immunodeficiency virus (SIV) challenges in rhesus monkeys. Adenovirus/poxvirus and adenovirus/adenovirus-vector-based vaccines expressing SIV(SME543) Gag, Pol and Env antigens resulted in an 80% or greater reduction in the per-exposure probability of infection against repetitive, intrarectal SIV(MAC251) challenges in rhesus monkeys. Protection against acquisition of infection showed distinct immunological correlates compared with post-infection virological control and required the inclusion of Env in the vaccine regimen. These data demonstrate the proof-of-concept that optimized HIV-1 vaccine candidates can block acquisition of stringent, heterologous, neutralization-resistant virus challenges in rhesus monkeys.

SUBMITTER: Barouch DH 

PROVIDER: S-EPMC3271177 | BioStudies | 2012-01-01

REPOSITORIES: biostudies

Similar Datasets

2015-01-01 | S-EPMC4653134 | BioStudies
2011-01-01 | S-EPMC3718279 | BioStudies
2013-01-01 | S-EPMC3846288 | BioStudies
2017-01-01 | S-EPMC5465370 | BioStudies
2019-01-01 | S-EPMC6358712 | BioStudies
2016-01-01 | S-EPMC4802495 | BioStudies
2010-01-01 | S-EPMC2937794 | BioStudies
1000-01-01 | S-EPMC3416332 | BioStudies
2013-01-01 | S-EPMC3594107 | BioStudies
1000-01-01 | S-EPMC4172223 | BioStudies